Topiramate Bioequivalence Study Brazil - Fast

NCT01439438 | Completed Phase 1

• 1 other identifier: 116144
• Study Type: interventional
• Target: 26
• Locations: 1 country
• Sites: 1

Brief Summary

This study is prospective, open-label, randomized, crossover, single dose, with 02 treatments, 02 sequences and 02 periods. The volunteers received, in each period, the reference or the test formulation, according to the randomization list, under fasting conditions, in order to evaluate if the reference and test formulations are bioequivalent.

Conditions

Epilepsy, Tonic-Clonic

Outcome Measures

Primary Outcomes (6)

• Area under curve of plasma concentration of drug from time 0 (zero) from time t (last measurable concentration)

  The area under the plot of plasma concentration of drug against time (non-compartimental method), after drug administration, defined as the area under the curve (AUC). The AUC 0-t is calculated from time 0 (prior to administration of medication) to time t (the time of the last quantifiable concentration), by linear trapezoidal rule. The AUC is of particular use in estimating the bioavailability of drugs, by measuring the extent of absorption.

  Collection points from time 0 to 192 hours evaluated in two periods

• Maximum observed concentration of drug through time (Cmax)

  Cmax is defined as the maximum or "peak" concentration of a drug observed after its administration. Cmax is one of the parameters of particular use in estimating the bioavailability of drugs, by measuring the total amount of drug absorbed. Measurement obtained directly of the plasma concentration curve of the drug (non-compartimental method). Occurring at Tmax.

  Collection points from time 0 to 192 hours evaluated in two periods

• Area under curve of plasma concentration of drug from the time 0 (zero) extrapolated to infinity (AUC0-inf)

  Measurement obtained directly from the plasma concentration curve of drug against time (non-compartimental method). AUC0-inf is calculated from time 0 (prior to administration of medication) extrapolated to infinity, by formula AUC0-inf=AUClast +Clast/Kel, where Clast is the Last measurable concentration and Kel is the first order rate constant associated with the terminal portion of the curve.

  Collection points from time 0 to 192 hours evaluated in two periods

• Time of maximum observed concentration (Tmax)

  Time when Cmax is obtained

  Collection points from time 0 to 192 hours evaluated in two periods

• Terminal half-life - T1/2

  Calculated by formula: T1/2\_Kel= Ln(2)/Kel.

  Collection points from time 0 to 192 hours evaluated in two periods

• First order rate constant associated with the terminal portion of the curve (Kel)

  This parameter is estimated by the angular coefficient of the regression line, calculated by the minimum squares method, of the natural logarithm of the concentration versus time for the last four concentrations values (or at least three) above the quantification limit

  Collection points from time 0 to 192 hours evaluated in two periods

Study Arms (2)

Test formulation

ACTIVE COMPARATOR

Test product: Topiramate 100 mg coated tablets produced by Dr. Reddy's Laboratories Ltd. in Period 1, followed by 28 days washout period during which no medication was administered; followed by reference product: Topamax® 100 mg coated tablets in Period 2

Drug: Topiramate coated tablet

Reference formulation

ACTIVE COMPARATOR

Topamax® 100 mg coated tablets marketed by Janssen-Cilag farmacêutica Ltda. in Period 1, followed by 28 days washout period during which no medication was administered; followed by test product: Topiramate 100 mg coated tablets produced by Dr. Reddy's Laboratories Ltd. in Period 2

Drug: Topamax® coated tablet

Interventions

Topiramate coated tablet DRUG

Test formulation

Test formulation

Topamax® coated tablet DRUG

Reference formulation

Reference formulation

Eligibility Criteria

• Age: 18 Years - 50 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Male
• Age between 18 and 50 years
• Body mass index between 19 and 28,5 kg/m2
• Good health conditions
• Capable to understand the study's nature and aim, including risks and adverse effects and with intention to cooperate with the researcher and to act in compliance with requirements of the assay, this will be confirmed by the informed consent's signature

You may not qualify if:

• The volunteer has a known hypersensitivity to the study drug (topiramate) or to compounds chemically related
• History or presence of hepatic or gastrointestinal illnesses, or other condition that interferes over the drug's absorption, distribution, excretion or metabolism
• History of hepatic, renal, pulmonary, gastrointestinal, epileptic, hematologic or psychiatric illness; hypo or hypertension of any etiologic that needs pharmacologic treatment; has history or had myocardial infarction, angina and/or heart insufficiency
• Non-recommended electrocardiographic findings, according to investigator criteria, for the study's participation
• The results of the laboratory exams are out of the values considered as normal according to this protocol's rules, unless that they are considered as clinically irrelevant by the investigator
• The volunteer is a smoker
• The volunteer ingests more than 5 cups of coffee or tea a day
• Has history of alcohol or drugs abuse
• Use any regular drug within the 02 weeks that preceded the beginning of the treatment and the assessment date, or employed any drug that can interfere with the study within one week
• The volunteer was hospitalized for any reason within 08 weeks of the beginning of this study's first period of treatment and the assessment date
• Treatment within the 03 previous months of the study with any known drug that presents toxic potential for important organs
• The volunteer participated in any experimental study or ingested any experimental drug within the 06 months that precede the beginning of this study and the assessment date
• The volunteer donated or lost 450 mL or more of blood within the 03 months that preceded to the study initiation or donated more than 1500 mL within 12 months between the beginning of the study and the assessment date
• Consume of inductive drugs and/or enzymatic inhibitors (CYP450 - hepatic), that are toxic for the organism or presenting long half-life's elimination within the 04 weeks that precede the study's initiation
• Consume of alcohol in 48 hours antecedents to the admission to the study and along the study period

Sponsors & Collaborators

• GlaxoSmithKline: lead

Study Sites (1)

GSK Investigational Site

Campinas, São Paulo, Brazil

Location

Related Links

• Results for study 116144 can be found on the GSK Clinical Study Register.

MeSH Terms

Conditions

Epilepsy, Tonic-Clonic

Condition Hierarchy (Ancestors)

Epilepsy, Generalized; Epilepsy; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases

Study Officials

• GSK Clinical Trials

  GlaxoSmithKline

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: OTHER
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 21, 2011
• First Posted: September 23, 2011
• Study Start: July 22, 2011
• Primary Completion: September 11, 2011
• Study Completion: September 11, 2011
• Last Updated: June 28, 2017

Record last verified: 2017-06

Locations

BR (1)